Physician profile
Mark Sedlak
NPI 1710522768
$1,313.70
in general payments reported to CMS, 2019-2025
17 companies · $169 in 2025
The $169 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $65.76 · 2022: $172 · 2023: $433 · 2024: $474 · 2025: $169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,076.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,076.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $545.98 | 2022-2025 | |
| Supernus Pharmaceuticals, INC. | $155.84 | 2023-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $116.51 | 2023-2024 | Auvelity |
| Corium, LLC | $87.50 | 2023-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $68.30 | 2024 | |
| Collegium Pharmaceutical, INC. | $64.41 | 2025 | Jornay Pm |
| Indivior INC. | $50.98 | 2021 | |
| Janssen Pharmaceuticals, INC | $36.15 | 2023-2024 | Spravato |
| Alkermes, INC. | $32.55 | 2023 | Lybalvi, Aristada |
| Teva Pharmaceuticals USA, INC. | $28.28 | 2023-2024 | Austedo Xr |
| Lundbeck LLC | $28.05 | 2022-2024 | Rexulti |
| Neurocrine Biosciences, INC. | $26.32 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $16.97 | 2023 | Rexulti |
| Genentech USA, INC. | $14.78 | 2021 | |
| Neos Therapeutics, LP | $14.53 | 2024 | Adzenys Xr-Odt |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $14.11 | 2023 | Aplenzin |
| Takeda Pharmaceuticals U.S.A., INC. | $12.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Sedlak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.